Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breas...
Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Gene-expression companion diagnostic tests, such as the Oncotype DX test, assess the risk of early stage Estrogen receptor (ER) positive (+) breast cancers, and guide clinicians in the decision of whether or not to use chemotherapy. However, these tests are typically expensive, time consuming, and tissue-destructive.
In this paper, we evaluate t...
Alternative Titles
Full title
Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a263529f5b0942a59b3b171495fb6472
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a263529f5b0942a59b3b171495fb6472
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-018-4448-9
